The estimated 5-year risk for the renal outcome was 2.4 vs 2.1% for people taking GLP-1 receptor agonists or SGLT-2 inhibitors vs those taking DPP-4 inhibitors. HealthDay News — For adults with type 2 ...

Tasimelteon significantly advanced sleep onset by 42.5 minutes in adults with delayed sleep-wake phase disorder, according to topline phase 3 data.

Supported by phase 3 FENhance 1, FENhance 2, and FENtrepid trial results, oral fenebrutinib reduced relapse rates and showed numerical benefits in delaying disability progression across the MS ...

Juvmo (tavapadon) offers a novel, selective D1/D5 dopamine receptor partial agonist mechanism for early monotherapy and adjunctive treatment in Parkinson disease.

Degevma (denosumab-adet) has received FDA approval as a biosimilar to Xgeva, demonstrating bioequivalence in safety, efficacy, and immunogenicity. The Food and Drug Administration (FDA) has approved ...

The effect of semaglutide on major adverse cardiovascular events (MACE) is only partially due to known risk factors, according to a study published online September 23 in the European Heart Journal.

Findings show reductions in inappropriate medication, medication underuse and overuse, and missing vaccinations ...

Phase 3 trial data show that zalunfiban administered on first medical contact significantly improved preprocedural coronary flow and 30-day clinical outcomes in STEMI.

The oral ALK2 inhibitor significantly reduced mean total new heterotopic ossification volume at 24 weeks in patients aged 12 ...

The Food and Drug Administration (FDA) has approved Jaypirca® (pirtobrutinib) for the treatment of adult patients with previously untreated chronic ...

Supported by phase 3 OASIS-4 data, elinzanetant significantly reduced daily hot flash frequency in women receiving endocrine therapy for HR-positive breast cancer.